Cardiac Complications Associated with COVID-19, MIS-C, and mRNA COVID-19 Vaccination

Pediatr Cardiol. 2022 Mar;43(3):483-488. doi: 10.1007/s00246-022-02851-x. Epub 2022 Mar 8.

Abstract

The COVID-19 vaccine is now approved for individuals greater than 5 years of age, but vaccination rates remain lower than expected in the pediatric age group. Misinformation and widespread reporting of vaccine-related myocarditis are contributing to vaccine hesitancy. When compared to severe cardiac complications that are associated with COVID-19, vaccine-related myocarditis has a milder presentation, is easily treated, and has a good prognosis. Acute COVID-19 has been associated with higher rates of myocarditis and myocardial injury. Multisystem inflammatory syndrome in children occurs weeks after initial infection with SARS-CoV-2 and can be associated with severe cardiovascular complications and death. Cardiac complications associated with acute COVID-19 and MIS-C are more severe and occur more frequently than myocarditis after mRNA COVID-19 vaccination. Furthermore, some of the academic and social disruptions caused by the pandemic expect to be eased by widespread vaccination. For all these reasons, COVID-19 vaccination is strongly recommended for all eligible age groups.

Keywords: COVID-19; Myocarditis; Vaccination.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / complications
  • COVID-19* / prevention & control
  • Child
  • Humans
  • RNA, Messenger
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • RNA, Messenger

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related